Result Announcement of clinical trial EPYDIS, phase III, for Givinostat, Italfarmaco Group
Italfarmaco Group announced the recommendation received for continuation of the clinical trial EPYDIS phase III for Givinostat in Duchenne Muscular Dystrophy.
Phase II analysis results showed that the administration of Givinostat in combination with corticosteroids show the progression of the disease.
For further information follow the link of the Press release:
Scientific Revisal:
Evgenia Oikonomidou – Scientific Advisor MDA Hellas – Biochemist MSc
(article from Scientific Announcements of MDA Hellas: : https://mdahellas.gr/oi-neyromyikes-pathiseis/episthmonikes-dhmosieuseis/)